Xencor, Inc
A biopharmaceutical company that engineers antibodies and other proteins to treat cancer and autoimmune diseases. Its XmAb platform makes precise "plug-and-play" tweaks to the stem of an antibody, and those engineered designs show up in approved drugs like Ultomiris and sotrovimab, as well as in therapies developed with partners such as Novartis and Amgen. Founded in 1997 by scientist Bassil Dahiyat in California, the company also runs its own pipeline of drug candidates.
Granted 97.3K · Sold 28.2K
Granted 24.9K · Sold 9.3K
Granted 18.7K · Sold 6.5K
Granted 19.5K · Sold 6.0K
Sold 5.1K
Sold 5.5K
Sold 5.5K
Sold 6.8K
Sold 7.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Dahiyat Bassil IPRESIDENT & CEO, Director · 4 transactions | +14.5% | 546.3K | 97.3K | — | 28.2K |
| Desjarlais John RSR. VICE PRESIDENT & CSO · 4 transactions | +6.3% | 263.8K | 24.9K | — | 9.3K |
| Eckert CeliaSVP, GENERAL COUNSEL · 4 transactions | +21.1% | 76.9K | 18.7K | — | 6.5K |
| Cornelissen Bart JanSR. VICE PRESIDENT & CFO · 3 transactions | +23.7% | 75.9K | 19.5K | — | 6.0K |
| Montgomery Alan BruceDirector · 1 transaction | -24.6% | 15.5K | — | — | 5.1K |
| Gustafson Kurt ADirector · 1 transaction | -27.1% | 14.7K | — | — | 5.5K |
| Ranieri Richard JDirector · 1 transaction | -28.5% | 13.7K | — | — | 5.5K |
| Feigal EllenDirector · 1 transaction | -35.7% | 12.3K | — | — | 6.8K |
| Gorman Kevin CharlesDirector · 1 transaction | -39.8% | 11.4K | — | — | 7.5K |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 6 months: -80.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.